Table 1 appears incorrectly in the published article. Please see the correct Table 1 and its legend below.
Table 1. Tumor characteristics and engraftment rate.
| Implanted (N) | Passaged (N, %) | P Value | ||
|---|---|---|---|---|
| Breast Cancer Subtype | TNBC | 13 | 7 (53.8%) | 0.02* |
| HER2+ | 3 | 1 (33.3%) | ||
| HR+ | 32 | 5 (15.6%) | ||
| NeoCT—Yes | TNBC | 9 | 5 (55.5%) | 0.02** |
| HER2+ | 2 | 1 (50%) | ||
| HR+ | 13 | 5 (38.5%) | ||
| NeoCT—No | TNBC | 4 | 2 (50%) | |
| HER2+ | 1 | 0 (0%) | ||
| HR+ | 19 | 0 (0%) | ||
| Response to NeoCT | Progressive Disease | 7 | 6 (85.7%) | 0.02*** |
| Stable Disease | 9 | 2 (22.2%) | ||
| Partial Response | 8 | 3 (37.5%) |
NeoCT: Neoadjuvant chemotherapy
*P value by Fisher exact analysis, comparing BCX engraftment in TNBC to HR+ breast cancer.
**P value by Fisher exact analysis, comparing BCX engraftment in NeoCT to no NeoCT implantations.
***P value by Fisher exact analysis, comparing BCX engraftment in tumors that progressed on NeoCT vs. those that had stable disease/partial response.
Reference
- 1.McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X, Zhao H, et al. (2015) Ability to Generate Patient-Derived Breast Cancer Xenografts Is Enhanced in Chemoresistant Disease and Predicts Poor Patient Outcomes. PLoS ONE 10(9): e0136851 doi:10.1371/journal.pone.0136851 [DOI] [PMC free article] [PubMed] [Google Scholar]